Dermata Therapeutics Inc. (DRMAW)
NASDAQ: DRMAW
· Real-Time Price · USD
0.02
0.00 (29.03%)
At close: Jun 09, 2025, 3:06 PM
Dermata Therapeutics Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -2.34M | -3.2M | -3.23M | -2.88M | -3.2M | -2.22M | -1.81M | -1.73M | -2.28M | -1.71M | -2.45M | -2.73M | -2.79M | -2.55M | -1.71M | -1.33M | -2.26M |
Interest Income | 36.22K | 49.35K | 52.5K | 54.64K | 69.3K | 85.86K | 92.77K | 31.05K | 37.54K | 42.09K | 21.49K | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -2.3M | -3.15M | -3.17M | -2.83M | -3.13M | -2.13M | -1.72M | -1.7M | -2.24M | -1.67M | -2.42M | -2.73M | -2.79M | -2.55M | -1.71M | -1.33M | -2.3M |
Net Income | -2.3M | -3.15M | -3.17M | -2.83M | -3.13M | -2.13M | -1.72M | -1.7M | -2.24M | -1.59M | -2.38M | -2.73M | -2.79M | -2.55M | -1.71M | -1.33M | -2.3M |
Selling & General & Admin | 1.06M | 1.01M | 824.29K | 874.64K | 1.6M | 1.08M | 909K | 893.48K | 1.09M | 822.33K | 892.78K | 1.12M | 1.19M | 1.44M | 912.49K | 462.77K | 1.58M |
Research & Development | 1.28M | 2.19M | 2.4M | 2.01M | 1.6M | 1.14M | 902.98K | 838.93K | 1.19M | 889.36K | 1.55M | 1.61M | 1.6M | 1.11M | 799.78K | 867.2K | 680.59K |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 2.34M | 3.2M | 3.23M | 2.88M | 3.2M | 2.22M | 1.81M | 1.73M | 2.28M | 1.71M | 2.45M | 2.73M | 2.79M | 2.55M | 1.71M | 1.33M | 2.26M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | 37.54K | n/a | n/a | n/a | 42.09K | 21.49K | n/a | n/a | 45.57M | 651.00 | 1.82K | 43.13K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 3.2M | 3.23M | 2.88M | 3.2M | 2.22M | 1.81M | 1.73M | 2.28M | 1.71M | 2.45M | 2.73M | 2.79M | 2.55M | 1.71M | 1.33M | 2.26M |
Income Tax Expense | n/a | 3.2M | n/a | n/a | -3.2M | -2.22K | -1.81K | -1.73K | n/a | -84.17K | -42.97K | -2.73M | -2.79M | -45.57M | -81 | -81 | -81 |
Shares Outstanding (Basic) | 5.15M | 1.55M | 1.55M | 676.57K | 444.06K | 3.93M | 3.19M | 2.7M | 65.72K | 770.12K | 767.27K | 699.68K | 520.54K | 8.35M | 311.27K | 469.74K | 520.54K |
Shares Outstanding (Diluted) | 5.15M | 1.55M | 1.55M | 676.57K | 444.06K | 3.93M | 3.19M | 2.7M | 65.72K | 770.12K | 767.27K | 699.68K | 522.03K | 8.35M | 311.27K | 469.74K | 520.54K |
EPS (Basic) | -0.45 | -2.04 | -2.04 | -4.18 | -7.06 | -0.54 | -0.54 | -0.63 | -34.08 | -2.06 | -3.1 | -3.9 | -5.35 | -0.31 | -5.5 | -2.84 | -4.43 |
EPS (Diluted) | -0.45 | -2.04 | -2.04 | -4.18 | -7.06 | -0.54 | -0.54 | -0.63 | -34.08 | -2.06 | -3.1 | -3.9 | -5.34 | -0.31 | -5.5 | -2.84 | -4.43 |
EBITDA | -2.34M | -3.2M | -3.23M | -2.88M | n/a | -2.13M | -1.81M | -1.73M | -2.28M | n/a | -2.45M | -2.73M | -2.79M | -2.55M | -1.71M | -1.33M | -2.26M |
EBIT | n/a | -3.2M | -3.23M | -2.88M | -3.2M | -2.22M | -1.81M | -1.73M | -2.28M | -1.71M | -2.45M | -2.73M | -2.79M | -2.55M | -1.71M | -1.33M | -2.26M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | 3.2M | 2.22M | 1.81M | 1.73M | n/a | 1.71M | 2.45M | 2.73M | 2.79M | 81.00 | 81.00 | 81.00 | 81.00 |